Serum albumin

Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended December 31, 2023

Retrieved on: 
Monday, February 12, 2024

NEW YORK, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported corporate updates and financial results for its fiscal third quarter ended December 31, 2023.

Key Points: 
  • NEW YORK, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported corporate updates and financial results for its fiscal third quarter ended December 31, 2023.
  • “We have laid a strong and exciting foundation for Immunovant,” said Pete Salzmann, M.D., chief executive officer at Immunovant.
  • Financial Highlights for Fiscal Third Quarter Ended December 31, 2023:
    Cash Position: As of December 31, 2023, Immunovant’s cash and cash equivalents totaled approximately $691 million.
  • IPR&D Expenses: There were no acquired in-process research and development expenses for the three months ended December 31, 2023.

Immunovant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential

Retrieved on: 
Tuesday, November 28, 2023

Four once-weekly SC injections of 600 mg IMVT-1402 reduced total IgG level by a mean of 74%, a potency that is similar to batoclimab at 680 mg that reduced IgG by 76% after 4 weekly doses.

Key Points: 
  • Four once-weekly SC injections of 600 mg IMVT-1402 reduced total IgG level by a mean of 74%, a potency that is similar to batoclimab at 680 mg that reduced IgG by 76% after 4 weekly doses.
  • In disease settings where batoclimab was administered continuously, a reduction of 80% was observed at steady state after about 6-8 weeks.
  • Across all doses evaluated, treatments with IMVT-1402 were generally well tolerated with only mild or moderate treatment-emergent adverse events observed.
  • Immunovant will host a conference call with accompanying slides and a simultaneous webcast today, November 28, 2023 at 8:00 a.m. EST to discuss the 600 mg multiple-ascending dose data.

Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential

Retrieved on: 
Tuesday, November 28, 2023

Four once-weekly SC injections of 600 mg IMVT-1402 reduced total IgG level by a mean of 74%, a potency that is similar to batoclimab at 680 mg that reduced IgG by 76% after 4 weekly doses.

Key Points: 
  • Four once-weekly SC injections of 600 mg IMVT-1402 reduced total IgG level by a mean of 74%, a potency that is similar to batoclimab at 680 mg that reduced IgG by 76% after 4 weekly doses.
  • In disease settings where batoclimab was administered continuously, a reduction of 80% was observed at steady state after about 6-8 weeks.
  • Across all doses evaluated, treatments with IMVT-1402 were generally well tolerated with only mild or moderate treatment-emergent adverse events observed.
  • Immunovant will host a conference call with accompanying slides and a simultaneous webcast today, November 28, 2023 at 8:00 a.m. EST to discuss the 600 mg multiple-ascending dose data.

Equillium Presents Positive Data from Phase 1b EQUALISE Study at the 2023 Annual Meeting of the American College of Rheumatology

Retrieved on: 
Monday, November 13, 2023

“It’s important that we saw both early and large reductions in proteinuria,” said Dr.

Key Points: 
  • “It’s important that we saw both early and large reductions in proteinuria,” said Dr.
  • Results are comparable to those observed in the Phase 3 AURORA1 study of voclosporin (ORR 70% at 6 and 12 months in active treatment).
  • Consistent with the decline in UPCR overtime, subjects were able to taper their systemic corticosteroids over the course of the study.
  • The poster presentation is available on the Presentations page of Equillium’s website under the Lupus tab.

Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended September 30, 2023

Retrieved on: 
Thursday, November 9, 2023

Financial Highlights for Fiscal Second Quarter Ended September 30, 2023:

Key Points: 
  • Financial Highlights for Fiscal Second Quarter Ended September 30, 2023:
    R&D Expenses: Research and development expenses were $48.0 million for the three months ended September 30, 2023, compared to $37.7 million for the three months ended September 30, 2022.
  • G&A Expenses: General and administrative expenses were $13.8 million for the three months ended September 30, 2023, compared to $11.9 million for the three months ended September 30, 2022.
  • Financial Highlights for Fiscal Six Months Ended September 30, 2023:
    R&D Expenses: Research and development expenses were $98.5 million for the six months ended September 30, 2023, compared to $66.2 million for the six months ended September 30, 2022.
  • Net loss for the six months ended September 30, 2023 and 2022 included $21.2 million and $15.8 million, respectively, related to non-cash stock-based compensation expense.

OmniAb Reports Third Quarter 2023 Financial Results and Business Highlights

Retrieved on: 
Thursday, November 9, 2023

OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and nine months ended September 30, 2023, and provided operating and partner program updates.

Key Points: 
  • OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and nine months ended September 30, 2023, and provided operating and partner program updates.
  • As of September 30, 2023, OmniAb had cash, cash equivalents and short-term investments of $96.6 million.
  • Financial results prior to November 1, 2022, are presented on a carve-out basis derived from Ligand’s historical accounting records, as if OmniAb were an independent company.
  • OmniAb management will review third quarter 2023 financial results as part of a Research & Technology virtual event being held today at 11:00 a.m. Eastern time.

Iteld Plastic Surgery Launches New Aesthetics Website

Retrieved on: 
Tuesday, October 31, 2023

The Iteld Aesthetics Institute site, which launched this summer, includes detailed information on services such as PRP and PRF , PRF EZ Gel plasma filler, Sculptra® biostimulatory fillers , and microneedling with exosomes.

Key Points: 
  • The Iteld Aesthetics Institute site, which launched this summer, includes detailed information on services such as PRP and PRF , PRF EZ Gel plasma filler, Sculptra® biostimulatory fillers , and microneedling with exosomes.
  • Patients who are seeking other types of surgical and non-surgical cosmetic procedures can find more details on various options on the main Iteld Plastic Surgery website.
  • For more information on natural non-surgical skin rejuvenation treatments, contact Chicago’s Iteld Plastic Surgery.
  • Call (312) 757-4505, fill out a contact form to schedule a consultation, or visit the Iteld Aesthetics Institute site for more details.

Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of Nephrology

Retrieved on: 
Monday, November 6, 2023

“The presentation at ASN represents current data from the EQUALISE study, which includes all but the last patient in the follow up period,” said Bruce Steel, chief executive officer at Equillium.

Key Points: 
  • “The presentation at ASN represents current data from the EQUALISE study, which includes all but the last patient in the follow up period,” said Bruce Steel, chief executive officer at Equillium.
  • “We are encouraged that we continue to see clinically meaningful response rates, particularly in these highly proteinuric subjects.
  • Results are comparable to those observed in the Phase 3 AURORA1 study of voclosporin (ORR 70% at 6 and 12 months in active treatment).
  • Consistent with the decline in UPCR overtime, subjects were able to taper their systemic corticosteroids over the course of the study.

Equillium Announces Abstracts Accepted for Presentation at the 2023 Annual Meetings of the American Society of Nephrology and the American College of Rheumatology

Retrieved on: 
Thursday, October 19, 2023

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that abstracts were accepted for poster presentations at the annual meetings of the American Society of Nephrology (ASN) and the American College of Rheumatology (ACR).

Key Points: 
  • Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that abstracts were accepted for poster presentations at the annual meetings of the American Society of Nephrology (ASN) and the American College of Rheumatology (ACR).
  • The abstracts highlight data from 17 Type B subjects in the Phase 1B EQUALISE study in highly proteinuric lupus nephritis patients (mean 24-hour urine protein creatinine ratio (UPCR) > 4 g/day).
  • This is in the setting of tapering the corticosteroids, stable kidney function (eGFR) and increasing serum albumin while on study.
  • Itolizumab was well tolerated when treated every 2 weeks for 24 weeks; with only 2 subjects reporting serious adverse events.

Immunovant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results

Retrieved on: 
Tuesday, September 26, 2023

“We are encouraged by the strong pharmacodynamic data observed to date with IMVT-1402,” said Pete Salzmann, M.D., chief executive officer of Immunovant.

Key Points: 
  • “We are encouraged by the strong pharmacodynamic data observed to date with IMVT-1402,” said Pete Salzmann, M.D., chief executive officer of Immunovant.
  • In the single-ascending dose (SAD) portion of the study, subcutaneously administered IMVT-1402 demonstrated a consistent reduction in IgG with potency that was similar to or greater than that of batoclimab.
  • Immunovant is also pleased to announce that initial MAD study results for the 300 mg cohort were released ahead of schedule today.
  • Immunovant will host a conference call with accompanying slides and a simultaneous webcast today, September 26, 2023 at 8:00 a.m. EDT to discuss the initial single-ascending dose and multiple-ascending dose data.